Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment

BMC Infectious Diseases

Table 1 Baseline Characteristics of Study Subjects, including subgroups.

	Sex:								HIV-1 RNA
	N	Age	M:F	CD4+	Duration of Infection^a	CDC Stage C3^b	ADC Stage	QNPZ-4 Score	Plasma	CSF	P-C log₁₀ Diff.	CSF WBC
		(yrs)	(ratio)	(cells/mm³)	(mean yrs +/- SD)	(percent)			(log₁₀RNA copies/mL)			(cells/mm³)
Total	100	39.0 (36.0–45.0)	91:9	181.5 (48.8 – 285.3)	9.7 (+/- 5.60)	70.3%	0 (0 – 1)	-0.50 (-1.53 – 0.21)	4.73 (3.52 – 5.15)	2.74 (1.48 – 4.00)	1.30 (0.19 – 2.32)	1.0 (0.0 – 4.0)
ADC ≥ 1 = 30.0%
Subdivision by Treatment Group and Effect
*Off Treatment*
	46	38.0 (33.5 – 43)	42:4	195.0 (33.5 – 307.5)	7.5 (+/- 5.80)	65.2%	0 (0 – 0.5)	-0.46 (-1.35 – 0.26)	4.93 (4.53 – 5.49)	3.61 (2.57 – 4.40)	1.19 (0.42 – 21.7)	2.0 (0 – 11.3)
ADC ≥ 1 = 23.1%
*On Treatment (Total)*
	54	43.0 (38.0-29.3)	49:5	181.5 (76.0 – 275.5)	11.09 (+/- 5.08)	75.9%	0.5 (0 – 1.0)	-0.51 (-2.62 – 0.20)	3.40 (1.85 – 4.80)	1.66 (1.28 – 3.07)	1.37 (0.0 – 2.42)	1.0 (0.0 – 2.0)
ADC ≥ 1 = 36.6%
*On Treatment Failures*
	36	40.0 (38.0 – 47.8)	32:4	166.5 (48.3 – 276.5)	11.24 (+/- 4.18)	75.0%	0.5 (0 – 1.0)	-0.42 (-2.40 – 0.25)	4.73 (3.99 – 5.04)	2.45 (1.45 – 3.64)	2.19 (1.29 – 2.59)	0.5 (0.0 – 2.8)
ADC ≥ 1 = 37.0%

Values are medians with IQR in parentheses beneath, unless noted. P-Clog₁₀ Diff. is the difference in plasma and CSF log₁₀ HIV concentrations.
^aData available for 49 of the 100 subjects.
^bData available for 81 of the 100 subjects; categorization based on the 1993 Centers for Disease Control HIV classification system.

ISSN: 1471-2334